The Danish pharmaceutical company Novo Nordisk aims to increase its revenue with the launch of Semaglutide 2.4, a new medication intended for the treatment of obesity and overweight. With this new drug, the company also hopes to reduce the demand for Ozempic, another of its products used in the treatment of these conditions that previously caused intermittent shortages in Mexico.
The CEO of Novo Nordisk in Mexico, Valney Suzuki, mentioned that Semaglutide 2.4 is being introduced in several countries, including Mexico. The company is already operating with this medication in approximately 15 nations, and significant growth is expected as it reaches more people. Although Suzuki did not specify growth expectations, he emphasized the importance of this new launch for the company.
Throughout 2024, Novo Nordisk achieved a net profit of 13.535 billion euros, primarily driven by income generated from treatments for diabetes and obesity, which experienced a 20% increase. Semaglutide 2.4 is presented as a solution to address both obesity and diabetes, thus avoiding the shortage of Ozempic, a drug initially intended for type 2 diabetes patients that was also used to assist with weight loss.
Regarding the availability of Semaglutide 2.4 in Mexico, the Federal Commission for the Protection against Health Risks (Cofepris) has already approved the medication, and it is expected to reach Mexican pharmacies by the end of April 2025. Valney Suzuki highlighted that efforts are being made to ensure an adequate supply of the new product for those patients interested in accessing the treatment, but the final public price has not yet been defined.
Mike Vivas, senior medical director of Novo Nordisk Mexico, assured that the company has enough Ozempic to treat patients with type 2 diabetes, as authorized, and now, with the arrival of Semaglutide 2.4, there will also be enough medication available for people with obesity and overweight who wish to use it. Mexico thus consolidates as a key market for Novo Nordisk by adding three approved medications to combat obesity and diabetes in the country.
